Expression of cyclin-dependent kinase inhibitor p21 in human liver

Hepatology

Volumn 28, Issue 3, 1998, Pages 738-743

  Crary, Gretchen S ^a   Albrecht, Jeffrey H ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; KI 67 ANTIGEN; PROTEIN P21;

ALCOHOL LIVER DISEASE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FATTY LIVER; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; LABELING INDEX; LIVER BIOPSY; LIVER CELL; LIVER DISEASE; LIVER FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031752378     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510280320     Document Type: Article

References (16)

1. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677.
2. Morgan DO. Principles of CDK regulation. Nature 1995;374:131-134.
3. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-1163.
4. Pines J. p21 inhibits cyclin shock. Nature 1994;369:520-521.
5. Harper JW, Elledge SJ. Cdk inhibitors in development and cancer. Curr Op Gen Develop 1996;6:56-64.
6. Michalopoulos GK, De Fances MC. Liver regeneration. Science 1997;276: 60-66.
7. Callea F, Brisigotti M, Fabbretti G, Sciot R, Van Eyken P, Favret M. Cirrhosis of the liver: a regenerative process. Dig Dis Sci 1991;36:1287-1293.
8. Kawasaki S, Imamura H, Bandai Y, Sanjo K, Idezuki Y. Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis. Gastroenterology 1992;102:1351-1355.
9. Farinati F, Cardin R, D'Errico A, De Maria N, Naccarato R, Cecchetto A, Grigioni W. Hepatocyte proliferative activity in chronic liver damage as assessed by the monoclonal antibody MIBI Ki67 in archival material: the role of etiology, disease activity, iron, and lipid peroxidation. HEPATOLOGY 1996; 23:1468-1475.
10. Tarao K, Shimizu A, Ohkawa S, Harada M, Ito Y, Tamai S, Kuni Y, et al. Development of hepatocellular carcinoma associated with increases in DNA synthesis in the surrounding cirrhosis. Gastroenterology 1992;103: 595-600.
11. Tarao K, Ohkawa S, Shimizu A, Harada M, Nakamura Y, Ito Y, Tamai S, et al. Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients. Cancer 1994;73:1149-1154.
12. Delhaye M, Louis H, Degraef C, Le Moine O, Deviere J, Gulbis B, Jacobovitz D, et al. Relationship between hepatocyte proliferative activity and liver functional reserve in human cirrhosis. HEPATOLOGY 1996;23:1003-1011.
13. Fang JW, Bird GL, Nakamura T, Davis GL, Lau JY. Hepatocyte proliferation as an indicator of outcome in acute alcoholic hepatitis. Lancet 1994;343:820-823.
14. WAF1/Cip1/Sdi1 gene expression in hepatic regeneration. HEPATOLOGY 1997;25:557-563.
15. Albrecht JH, Poon RYC, Ahonen CL, Rieland BM, Deng C, Crary GS. Involvement of p21 and p27 in the regulation of cdk activity and cell cycle progression in the regenerating liver. Oncogene 1998;16:2141-2150.
16. Wu H, Wade M, Krall L, Grisham J, Xiong X, Van Dyke T. Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development, and regeneration. Genes Dev 1996;10:245-260.